ERIC 2018 | Regulation of MRD in CLL: FDA and EMA
Peter Hillmen
• 25 Oct 2018
Progress in measurable residual disease (MRD) testing and use in the field of chronic lymphocytic leukemia (CLL) is advancing, as discussed here by Peter Hillmen, MD, ChB, of Leeds Teaching Hospital NHS Trust, Leeds, UK. Prof. Hillmen covers the progress made in regards to MRD regulation in the US and Europe in the CLL space, highlighting drug labeling and use as an endpoint in trials. This interview was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
